Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?

Samartzis EP, Samartzis N, Noske A, Fedier A, Caduff R, Dedes KJ, Fink D, Imesch P.

Mod Pathol. 2012 Jun;25(6):885-92. doi: 10.1038/modpathol.2011.217. Epub 2012 Feb 3.

2.

Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2012 Apr;25(4):615-24. doi: 10.1038/modpathol.2011.189. Epub 2011 Dec 9.

3.

Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.

Xiao W, Awadallah A, Xin W.

Int J Clin Exp Pathol. 2012;5(7):642-50. Epub 2012 Sep 5.

4.

Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.

Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG.

J Pathol. 2011 Jul;224(3):328-33. doi: 10.1002/path.2911. Epub 2011 May 18.

PMID:
21590771
5.

ARID1A mutations in endometriosis-associated ovarian carcinomas.

Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG.

N Engl J Med. 2010 Oct 14;363(16):1532-43. doi: 10.1056/NEJMoa1008433. Epub 2010 Sep 8.

6.

(Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes.

Borrelli GM, Abrão MS, Taube ET, Darb-Esfahani S, Köhler C, Chiantera V, Mechsner S.

Mol Hum Reprod. 2016 May;22(5):329-37. doi: 10.1093/molehr/gaw009. Epub 2016 Jan 31.

PMID:
26832958
7.

Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.

Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A.

Int J Gynecol Cancer. 2012 Jan;22(1):9-14. doi: 10.1097/IGC.0b013e318231f140.

8.

Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.

Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IeM.

Int J Gynecol Cancer. 2012 Oct;22(8):1310-5.

9.

Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1ß, p53, PTEN, BAF250a, and COX-2.

Lai CR, Hsu CY, Chen YJ, Yen MS, Chao KC, Li AF.

J Chin Med Assoc. 2013 Nov;76(11):629-34. doi: 10.1016/j.jcma.2013.07.008. Epub 2013 Aug 17.

10.

Loss of DLC1 is an independent prognostic factor in patients with oral squamous cell carcinoma.

Tripathi SC, Kaur J, Matta A, Gao X, Sun B, Chauhan SS, Thakar A, Shukla NK, Duggal R, Choudhary AR, DattaGupta S, Sharma MC, Ralhan R, Siu KW.

Mod Pathol. 2012 Jan;25(1):14-25. doi: 10.1038/modpathol.2011.145. Epub 2011 Oct 14.

11.

The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.

Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW 3rd, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL, Parkash V.

Mod Pathol. 2013 Aug;26(8):1101-10. doi: 10.1038/modpathol.2013.35. Epub 2013 Mar 22.

12.

Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer.

Cho H, Kim JS, Chung H, Perry C, Lee H, Kim JH.

Hum Pathol. 2013 Jul;44(7):1365-74. doi: 10.1016/j.humpath.2012.11.007. Epub 2013 Feb 18.

PMID:
23427874
13.

Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma.

Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu CH, Wang TL, Shih IeM.

Am J Surg Pathol. 2013 Sep;37(9):1342-8. doi: 10.1097/PAS.0b013e3182889dc3.

14.

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.

15.

ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.

Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, Petersen K, Kalland KH, Oyan AM, Akslen LA, Trovik J, Salvesen HB.

Mod Pathol. 2013 Mar;26(3):428-34. doi: 10.1038/modpathol.2012.174. Epub 2012 Oct 19.

16.

ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts.

Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke B, Schaeffer DF.

Hum Pathol. 2014 Jun;45(6):1258-68. doi: 10.1016/j.humpath.2014.02.006. Epub 2014 Feb 20.

PMID:
24767857
17.

Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.

Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IeM.

Int J Gynecol Pathol. 2012 Jul;31(4):297-303. doi: 10.1097/PGP.0b013e31823f8482.

18.

The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.

Chene G, Ouellet V, Rahimi K, Barres V, Provencher D, Mes-Masson AM.

Int J Gynaecol Obstet. 2015 Jul;130(1):27-30. doi: 10.1016/j.ijgo.2015.02.021. Epub 2015 Apr 11.

PMID:
25912412
19.

Expression of the G protein-coupled estrogen receptor (GPER) in endometriosis: a tissue microarray study.

Samartzis N, Samartzis EP, Noske A, Fedier A, Dedes KJ, Caduff R, Fink D, Imesch P.

Reprod Biol Endocrinol. 2012 Apr 20;10:30. doi: 10.1186/1477-7827-10-30.

20.

Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2012 Jan;25(1):122-30. doi: 10.1038/modpathol.2011.143. Epub 2011 Oct 7.

Items per page

Supplemental Content

Write to the Help Desk